Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study)

R. Díez Valle, J. Slof, J. Galván, C. Arza, C. Romariz, C. Vidal, Ricardo Díez Valle Dr., Pilar Teixidor i Rodriguez, Gloria Villalba Martínez, Jose Manuel Cabezudo Dr., Luis Miguel Bernal García Dr., Josep J.González Sánchez Dr., Enrique Ferrer Rodríguez Dr., Miguel Ángel Arraez Sánchez Dr., Gonzalo Olivares Granados Dr., Álvaro Toledano Delgado Dr., Gerardo Conesa Bertrán Dr., Juan José Acebes Martín Dr., Gerard Plans Ahicart Dr., Avelino Parajón Díaz Dr.Carlos Botella Asunción Dr., Ricardo Prat Acin Dr., Marta del Álamo de Pedro, Luis Ley Urzaiz Dr., Juan A. Barcia Dr., Juan R. Brin Dr., José María Torres Campa-Santamarina Dr., Ángel Maíllo Sánchez Dr., Jesús Merino Peña Dr.

Research output: Contribution to journalArticleResearchpeer-review

54 Citations (Scopus)


Objective: To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan®) in patients treated for malignant glioma under typical daily practice conditions in Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6). Material and methods: Retrospective review of data from 18 neurosurgery departments that were categorised as either using or not using 5-ALA. The study included adult patients with suspected malignant gliomas for whom the intended treatment plan included complete resection followed by radiotherapy and chemotherapy with temozolomide. Postoperative MRI and clinical data representing at least 6 months were required for inclusion. Rates of CR and PFS6 were compared between patients with 5-ALA treatment and those without. Results: The study included 251 evaluable cases. CR and PFS6 rates were significantly higher in the group of patients treated surgically with 5-ALA: CR, 67% versus 45%, p=.000; PFS6 for patients with grade IV tumours, 69% versus 48%; p=.002. The differences retained their significance and magnitude after adjusting for all covariates including age, functional status, and whether gliomas were located in eloquent areas. Conclusions: In this retrospective series, use of 5-ALA during habitual surgical procedures in Spain was associated with a higher complete resection rate for malignant glioma and increased PFS6 for grade iv glioma. © 2013 Sociedad Española de Neurología.
Original languageEnglish
Pages (from-to)131-138
Issue number3
Publication statusPublished - 1 Jan 2014


  • 5-aminolevulinic acid
  • Complete resection
  • Fluorescence image-guided surgery
  • Glioblastoma
  • Malignant glioma
  • Progression free survival


Dive into the research topics of 'Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study)'. Together they form a unique fingerprint.

Cite this